The goal of this project is to conduct simulation analyses using an existing dataset (from our AHRQ-funded PRIMA study) to assess the possible risks and benefits of immunoprophylaxis among babies 35-36 weeks gestation.
RSV immunoprophylaxis impact on RSV Morbidity and Asthma in Healthy Preterm Infants
Investigator: Escobar, Gabriel
Funder: National Heart, Lung, and Blood Institute
